Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. : Open clinical trial, controlled for the evaluation of the efficacy and safety of using Nimotuzumab in patients with triple-negative breast cancer. Phase II / III.

Medienart:

Klinische Studie

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

WHO International Clinical Trials Registry Platform - (2023) vom: 29. Mai Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Links:

Volltext [kostenfrei]

Themen:

610
Medical Condition: Metastatic Triple Negative Breast Cancer
Phase: Phase 2/Phase 3
Recruitment Status: Recruiting
Study Type: Interventional

Anmerkungen:

WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 23-05-2014, Last updated: 2023-06-05

ICTRP ID:

RPCEC00000178
IIC RD-EC150

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

CTG004795156